RxDoctor Payments DataLook up a doctor →

Steven Larsen, NP

Nurse Practitioner · Provo, UTNPI 1699877316

Payments from drug & device makers

$11,217in general payments, 2019–2025

Across 536 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$895
  • Astellas Pharma US Inc$821
  • Daiichi Sankyo Inc.$703
  • Lilly USA, LLC$682
  • Johnson & Johnson$678
  • Novartis$541
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$9,80487%
  • Education$1,41313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)43$895
Astellas Pharma US Inc23$821
Daiichi Sankyo Inc.41$703
Lilly USA, LLC37$682
Johnson & Johnson(2 entities)29$678
Novartis26$541
Gilead(2 entities)28$533
Incyte Corporation19$501
Pfizer32$476
Bayer24$427
Takeda Pharmaceuticals U.S.A., Inc.20$373
Merck16$356
Sanofi15$326
EMD Serono, Inc.14$270
Amgen11$242
Eisai Inc.12$230
AbbVie10$198
E.r. Squibb & Sons, L.L.C.10$191
Bristol Myers Squibb9$176
Regeneron Healthcare Solutions, Inc.8$173
Genentech USA, Inc.7$172
Pharmacyclics LLC, An Abbvie Company7$160
AVEO Pharmaceuticals, Inc.4$138
Sobi, Inc4$117
GSK6$113
Recordati_rare_diseases_inc.4$107
Novo Nordisk6$102
Tersera Therapeutics LLC4$102
Sanofi-aventis U.S. LLC1$100
Exeltis, USA Inc.2$97
Genmab U.S., Inc.4$83
Karyopharm Therapeutics Inc.4$78
Sumitomo Pharma America, Inc.4$78
Seagen Inc.4$75
Rigel Pharmaceuticals, Inc.3$65
Pharmaessentia USA Corporation4$65
Myovant Sciences Inc.4$60
Axsome Therapeutics, Inc.3$50
Jazz Pharmaceuticals Inc.3$50
Immunogen, Inc.1$47
Deciphera Pharmaceuticals Inc.2$40
Foundation Medicine, Inc.2$38
Pharmacosmos Therapeutics Inc.2$38
Caris MPI, Inc.2$38
Helsinn Therapeutics (U.S.), Inc.2$37
Renalytix AI, Inc.2$36
Tempus AI, Inc2$34
Agios Pharmaceuticals, Inc.2$33
Mylan Institutional Inc.1$26
Azurity Pharmaceuticals, Inc.1$25
Dova Pharmaceuticals1$25
Celltrion USA Inc.1$22
Novocure Inc.1$20
Dendreon Pharmaceuticals LLC1$18
CTI Biopharma Corp.1$17
Array Biopharma Inc1$17
Radius Health, Inc.1$17
Kyowa Kirin, Inc.1$17
Stemline Therapeutics Inc.1$17
Coherus Oncology, Inc.1$16

How this compares

$11,217 in reported general payments places this provider in the 95th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$238,112
Medicare patients
384
Services billed
11,765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib12$151,220
Imatinib Mesylate23$45,483
EliquisApixaban30$29,306
Hydroxyurea52$1,271
Anastrozole75$1,158
Gabapentin57$986
Exemestane12$627
Tamoxifen Citrate13$319
Letrozole15$288
Trazodone Hcl24$284
Zolpidem Tartrate21$247
Levothyroxine Sodium13$173
Omeprazole14$140
Alendronate Sodium13$93
Prednisone11$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$160$151,22012 claims
PfizerEliquis$476$29,30630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →